

Phase 2a (therapeutic exploratory) trial of SB17170 inpatients with idiopathic pulmonary fibrosis

SPARK Biopharma



RESPIRATORY	Phase 2
Product Type	Small molecules
Indication	Idiopathic pulmonary fibrosis (IPF)
Target	HMGB1 (High mobility group box 1)
MoA(Mechanism of Action)	SB17170 is a First-in-Class small molecule HMGB1 inhibitor targeting multiple pathological drivers of IPF, including inflammation, oxidative stress, and fibrosis.
Competitiveness	• First-in-Class HMGB1 inhibitor • Multi-Pathway Modulation: inflammation, oxidative stress, and fibrosis • Dosing Convenience: Oral & Once daily • Favorable Safety Profile observed (Clinical Phase 1, 2a) • Potential Combination with SoC
Development Stage	Phase 2
Route of Administration	Oral, Once Daily

Any unauthorized distribution or reproduction of this material is strictly prohibited.